Atossa declares stapled CVRs giving holders 25% of first PRV proceeds, $50M cap; record date Oct 19, 2026

ATOSSA THERAPEUTICS, INC.

Board declared one stapled CVR per ATOS share outstanding at the Oct 19, 2026 record date; shares issued after that also carry one CVR until detachment or expiry.
CVR holders get 25% of net proceeds from sale or deemed monetization of Atossa's first qualifying FDA priority review voucher, capped at $50M aggregate.
CVRs apply to a first qualifying PRV awarded on or before Dec 31, 2036 (Board may extend); no PRV has been awarded and (Z)-endoxifen is not approved for any indication.
(Z)-endoxifen holds FDA Rare Pediatric Disease Designation for Duchenne muscular dystrophy and McCune-Albright syndrome; VStock Transfer, LLC is rights agent.
CVRs stay stapled to shares with no separate CUSIP or trading; using the voucher or a change of control while unsold is a deemed monetization valued by an independent advisor.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.